Drugs / VH4524184
VH4524184
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07636928 | Jun → Aug 2026 overdue | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 1 | NCT07066722 | Jul → Dec 2025 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT06310551 | Mar 2024 → Jan 2028 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 1 | NCT06310616 | Mar → Aug 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT05631704 | Dec 2022 → Jul 2023 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07202546 | Feb 2026 → Jul 2027 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 2 | NCT06214052 | Feb → Jun 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-02-25 | GlaxoSmithKline | Results ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing gsk.com ↗
Results show a single-dose injection could maintain drug levels for up to six months. |
| 2026-02-25 | ViiV Healthcare | Results ViiV HEALTHCARE PRESENTS PIPELINE DATA FOR TWO INVESTIGATIONAL HIV TREATMENT THERAPIES WITH POTENTIAL FOR TWICE-YEARLY DOSING viivhealthcare.com ↗
Results show a single-dose injection could maintain drug levels for up to six months. |
| 2025-03-11 | GlaxoSmithKline | Results ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1 gsk.com ↗
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from two phase IIa proof-of-concept studies of investigational antiretroviral therapies VH4524184 (VH184) and VH4011499 (VH499). |
| 2025-03-11 | ViiV Healthcare | Results ViiV HEALTHCARE SHOWCASES LEADERSHIP IN LONG-ACTING INJECTABLES INNOVATION AT CROI 2025 WITH DATA ON THIRD-GENERATION INTEGRASE INHIBITOR (INSTI) AND HIGHLY POTENT CAPSID INHIBITOR AGAINST HIV-1 viivhealthcare.com ↗
VH4524184 (VH184), a potent, investigational third-generation integrase inhibitor (INSTI), demonstrates strong antiviral activity and positive safety results across multiple dose levels in people with HIV-1, supporting further development as a long-acting injectable antiretroviral |
| 2025-03-09 | GlaxoSmithKline | Results ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025 gsk.com ↗
A proof-of-concept clinical study with VH4524184 (VH184), an investigational third-generation integrase inhibitor with potential for long-acting dosing, assessed the drug’s exposure-response relationship to HIV-1 at multiple doses and shows findings that support further development9. |
| 2025-03-09 | ViiV Healthcare | Results ViiV HEALTHCARE CONTINUES TO DELIVER LONG-ACTING INJECTABLE HIV INNOVATION WITH LATE-BREAKING DATA AND REAL-WORLD INSIGHTS ACROSS PIPELINE AND PORTFOLIO AT CROI 2025 viivhealthcare.com ↗
A proof-of-concept clinical study with VH4524184 (VH184), an investigational third-generation integrase inhibitor with potential for long-acting dosing, assessed the drug’s exposure-response relationship to HIV-1 at multiple doses and shows findings that support further development. |
| 2024-07-23 | GlaxoSmithKline | Results ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor gsk.com ↗
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today shared positive in vitro findings showing that an investigational integrase strand transfer inhibitor (INSTI), VH4524184 (VH184), retained its antiviral activity and could be effective in countering second-generation INSTI resistance. |
| 2024-07-23 | ViiV Healthcare | Results ViiV HEALTHCARE PREMIERES EARLY DATA SHOWING ANTIVIRAL ACTIVITY AGAINST INTEGRASE RESISTANCE FROM ITS INVESTIGATIONAL, THIRD-GENERATION INTEGRASE INHIBITOR viivhealthcare.com ↗
Additional analysis presented of a phase I study showed pharmacokinetic (PK) and safety data supported further development of VH184. |
All press releases naming this drug 8 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VH4524184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07066722 ↗ |
| Known as | [14C]VH4524184 | “Drug: [14C]VH4524184” NCT07636928 ↗ |
| Known as | GSK4524184 | “This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy...” NCT05631704 ↗ |
| Known as | VH-184 | “VH4524184 (VH-184) is an emerging third-generation integrase strand transfer inhibitor (INSTI) with an enhanced in vitro resistance profile compared with second-generation...” PMID 42283218 ↗ Jun 20261“VH4524184 (VH-184) is a third-generation INSTI with long-acting potential currently in development for HIV-1 treatment.” PMID 40117383 ↗ Oct 2025 |
| Action | Inhibit | “Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.” PMID 40117383 ↗ Oct 2025 |
| Route | Oral | “This double-blind, randomized, placebo-controlled, phase 1, first-time-in-human (FTIH) study evaluated oral VH-184 in adults without HIV-1 administered as single ascending...” PMID 40117383 ↗ Oct 2025 |